Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Multiple Sclerosis

  Free Subscription


1 Acta Neuropathol
1 Ann Neurol
1 Can J Neurol Sci
2 J Immunol
2 J Neuroimmunol
1 J Neurol
1 J Neurol Neurosurg Psychiatry
2 J Neurol Sci
2 Mult Scler

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neuropathol

  1. DE BOER A, van den Bosch AMR, Mekkes NJ, Fransen NL, et al
    Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.
    Acta Neuropathol. 2024;147:90.
    PubMed         Abstract available

    Ann Neurol

  2. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    PubMed         Abstract available

    Can J Neurol Sci

  3. OH J, Bhan V, Traboulsee A, Morrow SA, et al
    Health Canada drug approval process: a barrier to personalized care in multiple sclerosis.
    Can J Neurol Sci. 2024 May 23:1-12. doi: 10.1017/cjn.2024.

    J Immunol

  4. VEMULAWADA C, Renavikar PS, Crawford MP, Steward-Tharp S, et al
    Disruption of IFNgamma, GZMB, PRF1, or LYST Results in Reduced Suppressive Function in Human CD8+ T Cells.
    J Immunol. 2024;212:1722-1732.
    PubMed         Abstract available

  5. FRANK C, Salapa HE, Allen KJH, Levin MC, et al
    Antibody-Mediated Depletion of Autoreactive T Lymphocytes through PD-1 Improves Disease Outcomes and Visualizes T Cell Activation in Experimental Autoimmune Encephalomyelitis.
    J Immunol. 2024 Apr 5:ji2300751. doi: 10.4049/jimmunol.2300751.
    PubMed         Abstract available

    J Neuroimmunol

  6. SRIRAM S, Kim KW, Ljunggren-Rose A
    Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
    J Neuroimmunol. 2024;392:578371.
    PubMed         Abstract available

  7. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
    As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    J Neuroimmunol. 2024;391:578368.
    PubMed         Abstract available

    J Neurol

  8. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
    The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
    J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
    PubMed         Abstract available

    J Neurol Neurosurg Psychiatry

  9. NICHOLAS R, Tallantyre EC, Witts J, Marrie RA, et al
    Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales.
    J Neurol Neurosurg Psychiatry. 2024 May 23:jnnp-2024-333532.
    PubMed         Abstract available

    J Neurol Sci

  10. SKARLIS C, Papadopoulos V, Raftopoulou S, Mavragani CP, et al
    Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    J Neurol Sci. 2024;461:123046.
    PubMed         Abstract available

  11. JAKIMOVSKI D, Qureshi F, Ramanathan M, Jalaleddini K, et al
    Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation.
    J Neurol Sci. 2024;461:123055.
    PubMed         Abstract available

    Mult Scler

  12. AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al
    Stimulus-related modulation in the 1/f spectral slope suggests an impaired inhibition during a working memory task in people with multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777.
    PubMed         Abstract available

  13. MENG D, Sacco R, Disanto G, Widmer F, et al
    Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.